Emily Chaddock survived severe preeclampsia at 27 weeks; daughter Mia born under 2 lbs. No drugs exist to prevent it. Eli ...
AAFP CEO Shawn Martin plans to push Congress to codify ACIP’s funding and structure, limiting HHS power after RFK Jr.’s ...
RevMed's Rasonque nets $198M; Madrigal sued over Rezdiffra data; Rezera eyes $181M IPO; ANI bids $560M for Egetis; Cloudbreak ...
Ellipsis, which uses voice AI to screen and chat with patients, bought Kouper Health, which carries out ...
Oxford spinout Alethio raises $90M Series A co-led by Sofinnova and RA Capital to take ET antibody ATX-011 into the clinic.
Caldera Therapeutics is going back to its existing partner Qyuns Therapeutics for a IL-17xTL1A bispecific antibody, while Evommune chose Hinova Pharmaceuticals for an oral molecular glue degrader.
Kamau Therapeutics shares early data on nula-cel 2.0 for sickle cell disease; 3 patients show no pain crises or transfusion ...
Sanofi drops SAR448272, a STAT6 degrader developed with Nurix Therapeutics, after Phase 1 discontinuation. Nurix shares fell ...
Biotech pessimism about China more than doubles in Q3 BPSI, making it biopharma’s No. 2 worry, while Big Pharma stays net ...
Endpoints’ Drew Armstrong and Max Bayer join policy expert Nick Shipley live Wednesday to break down what the US midterms ...
Marty Makary resigned as FDA commissioner on Tuesday after a turbulent tenure at the head of the agency. Makary was scheduled to sit down with senior reporter Max Bayer this week at the ...
Pfizer CEO Albert Bourla says Trump’s MFN pricing deals will hold through the end of the term, even if Democrats win Congress ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results